Smad4 was initially identified as a frequent deletion target in pancreatic carcinomas, and Smad4 deletions or mutations were also found in colon, breast, and lung cancers, albeit with less frequency [30]. Here, SMAD4 is linked to exocrine pancreatic carcinoma.